Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=-keywords
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-keywords", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-keywords", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=-keywords", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=-keywords" }, "data": [ { "type": "Grant", "id": "9236", "attributes": { "award_id": "1U18FD006993-01", "title": "Assessment of Zoonotic Risk of Emerging Infections in Companion Animals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-15", "end_date": "2025-08-31", "award_amount": 125600, "principal_investigator": { "id": 24972, "first_name": "Laura Brunengraber", "last_name": "Goodman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24973, "first_name": "Michael J", "last_name": "Stanhope", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This project evaluates the zoonotic implications of two important possible pathogens of companion animals: E. coli and coronaviruses. E. coli is the most common pathogen tested for antibiotic susceptibility in veterinary diagnostic labs. It is also one of the most concerning for multi-drug resistance; several isolates captured thus far in Vet-LIRN active surveillance are predicted to be pan-resistant to all drugs used in human or animal medicine. Our group has published the first animal host specific E. coli virulence database compatible with tools that can mine whole genome sequencing data. We now propose a comparative evolutionary genomic study to assess the potential of E. coli in dogs to encode novel resistance mechanisms and cause disease in humans. The data will be explored employing the latest developments in bacterial pan- genomic analysis, as well as bacterial GWAS. Such analysis will reveal if there are E. coli loci adapted to dogs, whether such loci have the functional character suggestive of pathogenic potential, and whether dogs may be a reservoir of potential pathogenesis or antibiotic resistance. The present outbreak of coronavirus disease caused by SARS-CoV-2 (COVID-19) is the third documented spillover of an animal coronavirus to humans to have resulted in a major epidemic, within the past two decades. Characterizing the species diversity of coronaviruses from companion animals, represents an important necessary step towards improving our understanding of virus–host interactions and to enhance our preparedness for future outbreaks. We will undertake this characterization in three different host species – horses, cats, and dogs – making use of an extensive set of time series samples (respiratory and feces) that comprise the AHDC’s collection. Sequences of coronavirus genomes will be acquired using two approaches: RNAseq of the respiratory virome and multiplexed amplicon approaches of both respiratory and feces samples; the former will allow us to identify the coronavirus species repertoire of each host, including the identification of any new coronavirus species, the latter will provide the ability to explore aspects of diversity in detail, within and between hosts. Comparative evolutionary genomic analyses of the data will inform on a wide variety of issues related to their zoonotic potential, including for example: (1) Which coronavirus species are more prone to inter-host transmission and is there a directionality to that transmission? (2) Are their host reservoirs for any of the virus species? (3) Which have a history of recombination? (4) Which have a history of molecular adaptation and what viral proteins does that involve? Our final aim is to provide eight other Vet-LIRN sequencing laboratories with the reagents and training to be able to independently sequence and analyze bacterial and viral genomes, including SARS-CoV-2. All three Aims of this project directly support the mission of the FDA to ensure the safety of our nation's food supply and protect public health.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9256", "attributes": { "award_id": "3U01FD007064-01S1", "title": "Assessing the impact of COVID-19 on opioid crisis and incorporating it in the FDA's opioids systems model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24987, "first_name": "Lucas", "last_name": "Glos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2021-08-31", "award_amount": 249950, "principal_investigator": { "id": 24988, "first_name": "Mohammad S.", "last_name": "Jalali", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this project is to expand FDA's current opioids systems model to enable multidimensional outcomes and cost-effectiveness analyses. Steep increases in opioid misuse and disorder, overdoses, and deaths since the 1990s represent a public health crisis with far-reaching impacts on society. Rising OUD and overdose deaths are linked with the decline in life expectancy in the United States each year from 2015 to 2017, which was the first multi-year decrease since 1993. While mortality is clearly an important outcome to consider when analyzing the effects of a policy, decision makers and stakeholders also care about how policies affect other outcomes that matter to society. This project will expand FDA's opioids systems model to include additional outcomes and enable cost-effectiveness analyses of policies and interventions meant to reduce opioid misuse, OUD, and overdose. We will develop the proposed model expansion as a team of experts with extensive experience in health economics and outcomes research, simulation modeling, and substance use disorder health science and policy. We will first expand the model to include additional impacts of opioid misuse, OUD, and overdose on quality of life and productivity loss, and societal costs to criminal justice and health care systems (Aim 1). We will then estimate costs and examine both intended and unintended outcomes associated with interventions and policy changes meant to reduce misuse, OUD, and fatal and non-fatal overdose (Aim 2). Finally, we will examine potential policy strategies under the frameworks of effectiveness and cost-effectiveness analyses. In these analyses, we will compare the effectiveness and cost-effectiveness of combinations of interventions and policies meant to reduce opioid misuse, OUD, and overdose (Aim 3), such as implementation of prescription controls, expanded access to MOUD, and increased distribution of naloxone. These aims will ultimately deliver: 1) an expanded model that is able to represent new outcomes as well as costs; 2) insight for policymakers regarding how various combinations of policy options will affect these multidimensional outcomes; and 3) the ability to discern which policy options represent the most efficient allocation of resources while minimizing unintended consequences. The proposed model expansion and accompanying analyses will enable FDA's policy tool to broaden the lens through which FDA and other government agencies consider the impact of policy solutions meant to reduce opioid misuse, OUD, and overdose.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10314", "attributes": { "award_id": "1U18FD007722-01", "title": "COVID-19 Animal Testing Capacity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 19256, "principal_investigator": { "id": 26273, "first_name": "Eman", "last_name": "Anis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26274, "first_name": "Lisa", "last_name": "Murphy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "/ABSTRACT COVID-19 animal testing capacity Severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of Coronavirusdisease 19 (COVID-19), which is an ongoing global health concern. The widespreadnature of this zoonotic disease and the susceptibilityof some animal species includingcompanion animals (cats and dogs), zoo animals, farmed mink, and wildlifeto infection emphasizes the need of expanding SARS-CoV-2 testing in animals. Understanding the extent of SARS-CoV-2 infections of domestic and wild animals would provide the necessary evidence to better assess the implications of widespread human SARS-CoV-2 infections for animal health and welfare. Our lab already has an established protocol for testing animal samples for SARS-CoV-2 using a real-time PCR panel, however, the presence of a single PCR workstation to set up the PCR reagents for all the PCR diagnostic assays performed in our laboratory limits our ability to expand our animal SARS-CoV-2 diagnostic and surveillance testing capacity. We propose to purchase a PCR workstation and laboratory refrigerator. This additional equipment will allow us to conduct large scale surveillance for detecting SARS-CoV- 2 infections among wild and domestic animals.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10318", "attributes": { "award_id": "1K08HS028817-01A1", "title": "The cost of illness: The impact of COVID-19 on patient financial outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 23785, "first_name": "Linda", "last_name": "Franklin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2027-08-31", "award_amount": 152640, "principal_investigator": { "id": 26277, "first_name": "Nora V.", "last_name": "Becker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Candidate: Nora Becker, MD, PhD, is a primary care physician, health economist, and early career health services researcher. Her long-term career objective is to become an independent physician-investigator and national expert on the impact of illness on financial outcomes for women and vulnerable populations in order to inform policies to reduce disparities and protect patients from financial harm. Research Context: The financial consequences of illness—termed “financial toxicity”—are important patient outcomes. Financial toxicity has two components, objective financial burden and subjective financial distress, but the lack of available data has made it difficult to measure objective financial burden. Further, the existing measures of subjective financial distress are limited and heterogeneous. The SARS-CoV-2 (COVID-19) pandemic has made it even more important to develop new ways to estimate and understand the magnitude of financial toxicity following acute illness. Specific Aims: 1) Identify patient subgroups at highest risk for objective financial burden after COVID-19 infection; 2) Estimate the causal effect of COVID-19 infection on objective financial burden independent of economic trends during the pandemic and describe heterogeneity in outcomes by patient subgroup; 3) Assess subjective financial distress related to COVID-19 infection. Research Plan: In Aims 1 and 2, Dr. Becker will perform a novel data linkage of commercial credit report data, Blue Cross Blue Shield of Michigan (BCBSM) insurance claims, and zip code-level social determinants of health. In Aim 1 she will use machine learning methods to identify which patients are at highest risk of poor credit report outcomes after COVID-19 infection, and in Aim 2 she will use advanced econometric methods to estimate the effect of COVID-19 infection on credit report outcomes, independent of overall economic trends during the pandemic, and describe heterogeneity in outcomes by patient subgroups. In Aim 3, Dr. Becker will adapt, pilot, and administer a new COVID-19-specific survey measure of subjective financial distress. Together, these aims will comprehensively estimate the financial toxicity of COVID-19 infection. Career Development Plan: Dr. Becker will develop expertise in 1) machine learning methods, 2) newly developed advanced econometric methods, 3) primary data collection and survey methods, and 4) leadership and communication skills to disseminate her work effectively to inform policy change. Dr. Becker's training will be supported by close mentorship, advanced didactic coursework, participation in career development activities, and engagement with media and policymakers to share the results of her research. Research Goals: The goal of this research is to identify the financial effects of COVID-19 infection, and which patients are most at risk of financial harm following infection, to inform the development of policies to reduce disparities in financial outcomes and better protect patients from the financial consequences of illness.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10325", "attributes": { "award_id": "1R43CK000679-01", "title": "Lateral Flow-Electrochemiluminescent (LF-ECL) Test Strips and Portable Reader for Ultrasensitive Foodborne Pathogen Detection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 225000, "principal_investigator": { "id": 26285, "first_name": "John", "last_name": "Bruno", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1916, "ror": "", "name": "NANOHMICS, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract Nanohmics proposes to couple the extreme sensitivity of electrochemiluminescence (ECL) from traditional ruthenium trisbipyridine (Ru(bpy)3) or even more promising quantum dot (Qdot)-based ECL sensitivity with the portability, convenience and speed (~ 15 minutes) of lateral flow (LF) test strips to produce a menu of ultrasensitive assays for detection of the major foodborne pathogenic bacteria and viruses. LF strip assays are known for being rapid, highly affordable, and facile onsite diagnostics, but generally lack sensitivity and may miss detection of foodborne pathogens (false negative results) at low levels even in time-consuming enrichment cultures. In some cases, LF strip developers have turned to fluorescence for added sensitivity. But, fluorescence has innate autofluorescent background from the excitation of other biological materials in samples, thus limiting its sensitivity. And although chemiluminescence (CL) can be ultrasensitive due to its initial black background and high signal to noise ratios (SNRs), CL is difficult to control spatially on a test strip and requires temporal delays to allow it to reach stable equilibrium prior to measurement which limits reproducibility. However, ECL is simple to control by controlling the working electrode voltage (only about 1.25V), thus enabling battery-operated handheld readers too. ECL can amplify or accrue the signal over time each time the Ru(bpy)3 redox “wheel” is turned electrically to release another red photon, thus giving sensitivity comparable to radioisotopic methods when the ECL signal is integrated over time. Newer Qdot-based ECL techniques promise as much as a million- fold increase in ECL over Ru(bpy)3-antibody or aptamer tags as well. Thus, Nanohmics proposes to build on its recent CDC- funded Phase I and DoD/OSD-funded Phase II SBIR contracts that are enabling it to develop highly sensitive antibody LF test strips for Influenza A/B and SARS-CoV-2 fluorescent and ECL LF assays using Qdots. These Qdot-LF test strips will be compared with antibody- and DNA aptamer-Ru(bpy)3-based LF test strips in terms of ECL output and limits of detection (LOD) for foodborne pathogens (initially Listeria and Salmonella) in Phase I. The winning LF strip design will be used for development of a portable ECL LF test strip reader and more foodborne bacterial and virus assays in Phase II to deliver to the public the most sensitive and rapid handheld onsite foodborne pathogen tests to aid in rapid detection and control of foodborne disease outbreaks.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10329", "attributes": { "award_id": "1R43OH012425-01A1", "title": "Rapid Production of Metal Organic Framework - Fabrics for Air Filtration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24462, "first_name": "BRIDGETTE E", "last_name": "GARRETT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 259484, "principal_investigator": { "id": 26291, "first_name": "Nick", "last_name": "Cienski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1918, "ror": "", "name": "HAVA, INC.", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "A year and a half later after the pandemic, it is evident that wearing masks for personal and public health concerns is an ongoing matter, with events like the arrival and spread of the Delta and Omicron variants of SARS CoV-2. Although it is well known that the N95 masks are the “golden standard” for protection, the public still overwhelmingly prefers cloth-based masks, due to the uncomfortable feeling and lack of reusability of the N95 mask, and the ease of breathing of the cloth-based masks. ASTM International recently published the ASTM F3502-21 standard, which creates guidelines for the efficacy of “Barrier Face Coverings” that are neither medical masks nor respirators and are primarily directed towards cloth masks. However, there are very few masks that are fabric-based (without extra insert filters) that pass this standard, and none that are washable and reusable. The goal of our company, Hava Technologies, is to create a cloth mask that has the benefits of a traditional cloth mask, such as breathability and washability, while still passing the ASTM-F3502 standard for filtration efficacy. To do this, we utilize a novel technology called metal-organic frameworks (MOFs). The electrostatic-based filtration of MOFs has shown filtration efficacy approaching and matching the ASTM F3502 Level 1 standard. More interestingly, these MOF-fabrics show effective filtration after 25 wash cycles, showing the capability of these MOF-fabric based masks and filters to be truly washable and reusable for months. The proposal will focus on the following specific aims: 1. Creation of MOF-fabric with uniform ASTM F3502 Level 1 standard and ensuring safety during usage. 2. Washable MOF-fabrics simulating home use conditions, including hot water and detergents. 3. Large area production of MOF-fabrics using standard roll-to-roll coating processing, including a public health survey of attitudes towards mask wearing. Wearers of Hava MOF-coated fabric masks will benefit by breathing air with significantly higher filtration efficiency than uncoated cloth masks. It is reasonable to expect protective masks with increased efficiency in sub-micron filtering capability would reduce transmission of SARS CoV-2 and subsequently reduce COVID-19 incidence with its associated morbidity, mortality, and adverse economic impact. According to a recent market research report, the global mask market is expected to surpass $1.2B in 2020 (Research Drive 2020), showing a viable commercialization strategy for the company.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10331", "attributes": { "award_id": "1U18FD007725-01", "title": "Implementation and Evaluation of Two SARS-CoV-2 Assays for Companion Animal Testing to Expand Vet-LIRN COVID-19 Capacity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2024-08-31", "award_amount": 50938, "principal_investigator": { "id": 26293, "first_name": "Stephen Douglas", "last_name": "Cole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26294, "first_name": "Elizabeth M.", "last_name": "Lennon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a zoonotic disease that, in addition to its importance in the human pandemic, has caused spillover infection and onward spread in mink, white-tailed deer, and hamsters. New viral variants with different characteristics are constantly emerging, with different characteristics and in some cases, these variants are able to infect species of animals that were not originally susceptible. Therefore, ongoing surveillance through Vet-LIRN is essential for early recognition of spread within animals. Given that companion animals reside in 85 million US households, if SARS-CoV-2 were to gain the ability to spread amongst pets or between pets and humans, there could be immense public health consequence and consequence to wildlife populations. The objective of this proposal is to evaluate and validate novel testing methodologies including validating loop-mediated isothermal amplification (LAMP) in a variety of sample matrices in dogs and cats, and to perform rigorous evaluation of a commercially available ELISA kit. Our specific aims include: Aim 1: Assess the validity of a commercial colorimetric LAMP assay for the qualitative detection of SARS-CoV-2 RNA in 4 novel matrices collected from both dogs and cats. Aim 2: Validate a commercially available ELISA for SARS-CoV-2 antibodies in dogs and cats while building capacity to conduct SARS-CoV-2 serological testing. These aims will provide technician training, equipment, and expertise to provide capacity for SARS-CoV-2 testing in dogs and cats.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10340", "attributes": { "award_id": "1U01FD007689-01", "title": "Development and Experimental Verification of Fundamental Models to Enable Implementation of Microwave-Assisted Freeze Drying", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26302, "first_name": "Vivian", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 999448, "principal_investigator": { "id": 26303, "first_name": "Emily S", "last_name": "Gong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1919, "ror": "", "name": "PHYSICAL SCIENCES, INC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Physical Sciences Inc. (PSI), in collaboration with the University of Connecticut (UConn), and with industry participation form Merck, proposes to develop and verify a fundamental model of Microwave- Assisted Freeze Drying (MAFD) to enable its implementation for pharmaceutical manufacturing. This effort will leverage primary drying models of traditional shelf-based freeze drying in vials developed and tested with support from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Our goal is to develop a heat and mass transfer model of the primary drying, or ice sublimation phase of MAFD freeze- drying, the most time consuming and critical phase. The model will predict the temperature of the product throughout primary drying and the drying time based on input parameters for the container system (e.g. vial, tray or dual chamber syringe), the product formulation (e.g. dielectric properties, resistance to drying, etc.), and the process conditions (e.g. microwave frequency, microwave power, chamber pressure). This program supports the advancement of regulatory science to facilitate the implementation of emerging manufacturing technology in the pharmaceutical sector. Microwave-assisted freeze drying (MAFD) is emerging as an alternative to traditional freeze drying as MAFD can significantly reduce processing costs and time compared to traditional freeze drying while maintaining product efficacy and stability. For example, studies have shown an approximately 80% reduction in cycle time using MAFD over traditional freeze drying. MAFD has more commonly been used in the food industry, and has not been applied to drying of pharmaceutical products at a large scale. This is partially due to a lack of knowledge of formulation response to microwave energy, and heat and mass transfer in MAFD processes to ensure efficient process design while maintaining product quality attributes. The successful completion of this program will result in a heat and mass transfer model of MAFD and a database of formulation microwave power absorption that can be used by industry to enable implementation of MAFD processes. Transitioning from traditional freeze drying to MAFD will result in reduced processing costs and cycle times and enable more agile manufacturing including on-demand and semi-continuous processes. This effort is particularly relevant during this current global pandemic. Administration of the current COVID-19 vaccines was limited by cold chain storage requirements. As COVID-19 vaccination programs transition from emergency response to routine administration, the economics of production and distribution will become more crucial. It is likely that future development of the COVID-19 vaccines will focus on freeze drying for product stabilization and distribution. Many common vaccines require freeze-drying, including those to prevent measles, yellow fever, Hib, BCG, H1N1, etc. Development of economical freeze-drying cycles will be critical for production of COVID-19 vaccines in manufacturing facilities around the world.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10350", "attributes": { "award_id": "1R43OH012495-01", "title": "Moisture-resistant, sterilizable and reusable N-95 like piezoelectric facemask filtering membrane with long-term biodegradability", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24462, "first_name": "BRIDGETTE E", "last_name": "GARRETT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-08-31", "award_amount": 276415, "principal_investigator": { "id": 26312, "first_name": "Linh", "last_name": "Le", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26313, "first_name": "Thanh Duc", "last_name": "Nguyen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1922, "ror": "", "name": "PIEZOBIOMEMBRANE, INC.", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Facemasks have been shown to be the most effective tool to prevent the spreading and transmission of infectious viruses in pandemics. Many countries, including the US, have enforced the use of facemasks in public area or healthcare settings to protect healthcare workers and general population against highly contagious viral strains of the SARS-COVID-2. This global enforcement of facemasks has led to billions of N95/surgical masks (which are intended for single-use and are non-degradable) being disposed of in landfills and ocean, causing a significant crisis on the environment. Aside from viral infection, particulate matters (PMs, i.e. small particles with sizes at nano or micro-meters) from the combustion of fossil fuels around the world also has severe impact on human health. Especially, small particles such as PM1.0 or PM2.5 (i.e. sizes < 1 µm and 2.5 µm, respectively) are the most poisonous and harmful ones since they can travel into deeper parts of the respiratory tract and even penetrate into the bloodstream. In this regard, facemasks have also been the most effective solution to protect public health from industrial PMs and air pollution. Given such a tremendous demand of filtration facemask membranes, the heavy and continuous use of traditional non-degradable, one-time disposable facemasks (e.g. N95 and surgical masks) will not only be an economic burden but also cause an environmental crisis with billions of permanent plastic wastes disposed every year. Besides the environmental problem, current facemasks struggle with a significant drawback of losing filtration function after a long period of continuous use and exposure of humid air, thus making the mask users non-protective against the risk of viral infection. Herein, we propose a novel piezoelectric composite nanofiber mesh of Poly-L-Lactide (PLLA) and Magnesium Oxide (MgO) which provides all properties of an ideal filtering membrane, including (1) moisture- resistance, (2) good mechanical strength, (3) N95-like filtering efficiency, (4) small pressure-drop, (5) reusability/sterilize-ability, and (6) long-term biodegradation to avoid any harm on the environment. Our major hypothesis is that by creating a highly piezoelectric MgO/PLLA and then employ multi-layer of the MgO/PLLA nanofiber mesh with tunable pore size/pore number in each layer, we will be able to produce a desired filter with a high filtration efficiency and low pressure drop, similar to a N95 facemask filter. To achieve the facemask and demonstrate the hypothesis in this phase I SBIR, we design the project with two aims. Aims 1 (6 months) is to characterize the MgO/PLLA nanofiber membrane filter in terms of piezoelectric effect, mechanical property, and porosity of the nanofiber membrane. Aim 2 (12 months) is to fabricate the multi-layer filtering membrane with the MgO/PLLA nanofiber mesh patterned with micro-pores and achieve the N-95 performance in terms of filtering efficiency and pressure drop.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10352", "attributes": { "award_id": "1R43OH012416-01", "title": "Regenerative face mask with long shelf life and long service time for effective coronavirus filtration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25093, "first_name": "Marcienne", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2023-02-28", "award_amount": 243500, "principal_investigator": { "id": 26316, "first_name": "Bo", "last_name": "li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1923, "ror": "", "name": "POLYK TECHNOLOGIES, LLC", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "PolyK Technologies, LLC SBIR Phase I The outbreak of COVID-19 causes a soaring increase in demand of N95 masks, which can effectively filter out over 95% of coronavirus. Despite the dramatic supply-demand gap has been temporarily suppressed by the use of vaccines, the virus mutation and the misinformation holding back people from receiving the vaccine add complexity to the battle against the COVID virus. Currently, the infection rate begins to rise sharply in several states, and the mask mandate is being reinstated. It is unclear whether the looming increase of mask demands can be fulfilled. The electrostatic filter is the key element rendering N95 masks effective against minuscular airborne containminats, but also the one limiting the service time of the N95 masks. N95 masks have to be discarded after daily use (once surface charges are dissipated) and cannot be resued by cleaning or disinfection. Inspired by our experience in piezoelectric polymers, this project will develop a novel piezo/pyro filter for N95 masks. The piezo/pyro filters can generate can continuously generate substantial surface charges during breathing, therefore enabling effective filtration against minuscular COVID virus even after repetitive sanitization and sterilization. This project will address any shortage of N95 masks and similar PPE once and for all, by providing genuine resuable piezo masks with with high filtration efficacy, long service time, and regeneration capability (reusable after disinfection without sacrificing the filtration performance).", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1442, "count": 14420 } } }